Nishank Jain1,2, Bradley C Martin3, Junqiang Dai4, Milind A Phadnis4, Layth Al-Hindi1, Theresa I Shireman5, S Susan Hedayati6, Rafia S Rasu7, Jawahar L Mehta1,2. 1. Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas. 2. Medicine Service, Central Arkansas Veterans Affairs Medical Center, Little Rock, Arkansas. 3. Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, Arkansas. 4. Department of Biostatistics and Data Science, University of Kansas School of Medicine, Kansas City, Kansas. 5. Department of Health Services, Policy and Practice, Brown University, Providence, Rhode Island. 6. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. 7. Department of Pharmacotherapy, University of North Texas Health Sciences, Fort Worth, Texas.
Abstract
Background: Individuals aged ≥75 years are the fastest-growing population starting dialysis for end-stage kidney disease (ESKD) due to living longer with coronary artery disease. ESKD alone can increase bleeding risk, but P2Y12 inhibitor (P2Y12-I) antiplatelet medications prescribed for cardiovascular treatment can exacerbate this risk in patients with ESKD. The age-specific rates of bleeding complications in dialysis patients with ESKD on P2Y12-I remain unclear, as does how age modifies the bleeding risk from P2Y12-I use in these patients. Methods: In a retrospective cohort study, we collected data on 40,972 patients receiving maintenance hemo- or peritoneal dialysis who were newly prescribed P2Y12-I therapy between 2011 and 2015 from the USRDS registry. We analyzed the effect of age on the time to first bleed and the interactions between age and P2Y12-I type on modifying the effects of a bleed. Results: Twenty percent of the cohort were aged ≥75 years. There were 3096 (8%) gastrointestinal (GI) and 1298 (3%) intracranial (IC) bleeding events during a median follow-up of 1 year. Annual incidence rates for IC bleeds were 2% in those aged <55 years and 3% in those aged ≥75 years. Rates for GI bleeds were 4% in those aged <55 years and 9% in those aged ≥75 years. On clopidogrel, prasugrel, and ticagrelor, for every decade increase in age of the cohort members, the risk of IC bleed increased by 9%, 55%, and 59%, and the risk of GI bleed increased by 21%, 28%, and 39%, respectively. At age ≥75 years, prasugrel was associated with a greater risk of IC bleed than clopidogrel. At age ≥60 years, ticagrelor was associated with a greater risk of GI bleed than clopidogrel. Conclusions: More potent P2Y12-Is (prasugrel and ticagrelor) were associated with a disproportionately higher risk of IC bleed with increasing age compared with that of clopidogrel-prasugrel was much worse than clopidogrel at age ≥75 years. All three drugs were associated with only modest increase in the risk of GI bleed with every decade increase in age-ticagrelor was much worse than clopidogrel at ≥60 years of age. These results highlight the need for head-to-head clinical trials for the use of P2Y12-Is in patients with ESKD to determine age cutoffs where the risk of bleeding outweighs the benefits of thrombosis prevention.
Background: Individuals aged ≥75 years are the fastest-growing population starting dialysis for end-stage kidney disease (ESKD) due to living longer with coronary artery disease. ESKD alone can increase bleeding risk, but P2Y12 inhibitor (P2Y12-I) antiplatelet medications prescribed for cardiovascular treatment can exacerbate this risk in patients with ESKD. The age-specific rates of bleeding complications in dialysis patients with ESKD on P2Y12-I remain unclear, as does how age modifies the bleeding risk from P2Y12-I use in these patients. Methods: In a retrospective cohort study, we collected data on 40,972 patients receiving maintenance hemo- or peritoneal dialysis who were newly prescribed P2Y12-I therapy between 2011 and 2015 from the USRDS registry. We analyzed the effect of age on the time to first bleed and the interactions between age and P2Y12-I type on modifying the effects of a bleed. Results: Twenty percent of the cohort were aged ≥75 years. There were 3096 (8%) gastrointestinal (GI) and 1298 (3%) intracranial (IC) bleeding events during a median follow-up of 1 year. Annual incidence rates for IC bleeds were 2% in those aged <55 years and 3% in those aged ≥75 years. Rates for GI bleeds were 4% in those aged <55 years and 9% in those aged ≥75 years. On clopidogrel, prasugrel, and ticagrelor, for every decade increase in age of the cohort members, the risk of IC bleed increased by 9%, 55%, and 59%, and the risk of GI bleed increased by 21%, 28%, and 39%, respectively. At age ≥75 years, prasugrel was associated with a greater risk of IC bleed than clopidogrel. At age ≥60 years, ticagrelor was associated with a greater risk of GI bleed than clopidogrel. Conclusions: More potent P2Y12-Is (prasugrel and ticagrelor) were associated with a disproportionately higher risk of IC bleed with increasing age compared with that of clopidogrel-prasugrel was much worse than clopidogrel at age ≥75 years. All three drugs were associated with only modest increase in the risk of GI bleed with every decade increase in age-ticagrelor was much worse than clopidogrel at ≥60 years of age. These results highlight the need for head-to-head clinical trials for the use of P2Y12-Is in patients with ESKD to determine age cutoffs where the risk of bleeding outweighs the benefits of thrombosis prevention.
Authors: Robert Edfors; Anders Sahlén; Karolina Szummer; Henrik Renlund; Marie Evans; Juan-Jesus Carrero; Jonas Spaak; Stefan K James; Bo Lagerqvist; Christoph Varenhorst; Tomas Jernberg Journal: Heart Date: 2018-03-24 Impact factor: 5.994
Authors: Giuseppe Patti; Fabrizio D'Ascenzo; Ovidio De Filippo; Francesco Bruno; Sergio Leonardi; Alaide Chieffo; Mario Iannaccone; Christoph Liebetrau; Sergio Manzano-Fernández; Guglielmo Gallone; Pierluigi Omedè; Enrico Cerrato; Tim Kinnaird; Federico Conrotto; Francesco Piroli; Jose Paulo Simao Henriques; Wojciech Wańha; Edoardo Elia; Alberto Dominguez-Rodriguez; Sergio Raposeiras-Roubin; Emad Abu-Assi; Gaetano Maria De Ferrari Journal: Eur Heart J Qual Care Clin Outcomes Date: 2022-01-12
Authors: Nishank Jain; Milind A Phadnis; Suzanne L Hunt; Junqiang Dai; Theresa I Shireman; Clayton L Davis; Jawahar L Mehta; Rafia S Rasu; S Susan Hedayati Journal: Kidney Int Rep Date: 2021-07-03
Authors: Tara I Chang; Maria E Montez-Rath; Jenny I Shen; Matthew D Solomon; Glenn M Chertow; Wolfgang C Winkelmayer Journal: J Am Heart Assoc Date: 2014-10-21 Impact factor: 5.501